To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Gaithersburg company ...
Novavax (NASDAQ:NVAX) was downgraded to Underperform from Neutral at Bank of America, citing growth outlook challenges despite acknowledging the company’s strong execution and recent cost-cutting ...
Novavax, Inc. receives a Hold rating, reflecting improved prospects after its Sanofi partnership and upgraded 2025 revenue guidance to $1–1.05 billion. The SNY deal provides upfront payments, ...
Novavax, Inc. (NASDAQ:NVAX) shares are trading lower Thursday after the company announced it has extended its $225 million convertible notes deal. Additionally, B of A securities downgraded the stock ...
Novavax (NASDAQ:NVAX) has received regulatory approval in Japan for its COVID-19 vaccine, Nuvaxovid, which has resulted in a milestone payment from Takeda (NYSE:TAK) (OTCPK:TKPHF), the company said on ...
Investors with a lot of money to spend have taken a bearish stance on Novavax NVAX. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...
Novavax Inc said on Wednesday it has signed an agreement with the Australian government to supply 40 million doses of its COVID-19 vaccine candidate, NVX-CoV2373.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback